Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

Inclusion Criteria: * Patients willing and capable of providing written informed consent for study participation. * Adults 18 to 70 years of age. * Liver allograft from a deceased or living donor. * Treated with a CNI containing immunosuppressive regimen. * Liver transplant 6 to 24 months prior to screening. * Estimated kidney function between chronic kidney disease (CKD) IIIb/ 30 mL/min \< eGFR \< CKD II/60 mL/min with deteriorating renal function. * Acceptable graft function (according to liver enzymes (AST / ALT) and total bilirubin). Exclusion Criteria: * Multiple solid organ transplant recipients * Active chronic inflammatory bowel disease and recurrent autoimmune hepatitis * Malignant diseases other than neoplasms of the skin. * Patient on other investigational drug or presence of any hypersensitivity to the interventional drug. * Pregnant or nursing (lactating) women. * Women of child-bearing potential (physiologically capable of becoming pregnant, unless they are using effective methods of contraception). * Anemia, thrombocytopenia, leucopenia, uncontrolled hyperlipidemia or proteinuria * HIV positivity Other protocol-defined inclusion/exclusion criteria may apply.